Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 20/20 | 0.70 |
| ▸ | PPARA | Q07869 | 19/20 | 0.70 |
| ▸ | PPARD | Q03181 | 4/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6182078 | 0.94 | PPARG (0.66) | PPARGPPARAPPARD | |
| SCHEMBL6182074 | 0.92 | PPARG (0.65) | PPARGPPARAPPARD | |
| SCHEMBL6180496 | 0.91 | PPARG (0.68) | PPARGPPARAPPARD | |
| SCHEMBL6184878 | 0.90 | PPARG (0.65) | PPARGPPARAPPARD | |
| SCHEMBL6185898 | 0.90 | PPARG (0.69) | PPARGPPARAPPARD | |
| SCHEMBL6183136 | 0.90 | PPARG (0.72) | PPARGPPARAPPARD | |
| SCHEMBL20235377 | 0.89 | PPARG (0.87) | PPARGPPARAPPARD | |
| SCHEMBL14110611 | 0.88 | PPARG (0.72) | PPARGPPARAPPARD | |
| SCHEMBL6182079 | 0.88 | PPARG (0.64) | PPARGPPARAPPARD | |
| SCHEMBL14154285 | 0.87 | PPARG (0.74) | PPARGPPARAPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1492528-A1 | ANTIDIABETIC AGENTS | Warner-Lambert Company LLC (US) | 2005-01-05 | — | — | EP | claimed |
| US-6716842-B2 | NON-INSULIN DEPENDENT DIABETES MELLITUS, OBESITY, HYPERGLYCEMIA, HYPERLIPIDEMIA, HYPERCHOLESTEREMIA, ATHEROSCLEROSIS, HYPERTRIGLYCERIDEMIA, HYPERINSULINEMIA IN A MAMMAL | WARNER-LAMBERT COMPANY, LLC | 2004-04-06 | — | — | US | claimed |
| US-20030225083-A1 | Antidiabetic agents | FAKHOURY STEPHEN A (US) | 2003-12-04 | — | — | US | claimed |
| WO-2003084535-A1 | ANTIDIABETIC AGENTS | WARNER-LAMBERT COMPANY LLC (US) | 2003-10-16 | — | — | WO | claimed |
| US-6716842-B2 | NON-INSULIN DEPENDENT DIABETES MELLITUS, OBESITY, HYPERGLYCEMIA, HYPERLIPIDEMIA, HYPERCHOLESTEREMIA, ATHEROSCLEROSIS, HYPERTRIGLYCERIDEMIA, HYPERINSULINEMIA IN A MAMMAL | WARNER-LAMBERT COMPANY, LLC | 2004-04-06 | — | — | US | disclosed |
| US-20030225083-A1 | Antidiabetic agents | FAKHOURY STEPHEN A (US) | 2003-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225083-A1 | Antidiabetic agents | GPR119, IAPP, SLC5A1 | PPARG 181/4885PPARA 510/4885PPARD 407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.